Skip to content

Samuel Bulteau

Nantes Université, CHU Nantes, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, Nantes F-44000, France.

2 papers in the library · 3 citations · publishing 2026

Papers

Toward dimensional body consciousness impairments in post-traumatic stress disorder and its dissociative subtype: A predictive processing approach.

Neuroscience and biobehavioral reviews March 1, 2026 Andrew Laurin, Hugo Bottemanne, Samuel Bulteau et al. 2 citations

A review proposes that post-traumatic stress disorder (PTSD) involves disrupted body awareness, specifically the sense of body ownership and sense of agency, which current models overlook. Using predictive processing theory, it distinguishes two PTSD subtypes. In non-dissociative PTSD, hyperprecise trauma-related prior beliefs and heightened interoceptive signals (due to amygdala and anterior insula hyperactivity) produce rigid self-representations, with cognitive processing ranked as prior, interoception, then exteroception. In the dissociative subtype, emotional over-inhibition and anterior insula hypoactivity weaken priors and interoception, while exteroception dominates (exteroception, interoception, prior). Sense of agency impairments are specific to the dissociative subtype, linked to angular gyrus hyperactivity and glutamate hypofunction. The framework suggests a dimensional model of body consciousness disruption across the PTSD spectrum and discusses therapeutic implications for top-down and bottom-up interventions.

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series.

European journal of psychotraumatology December 1, 2026 Maud Rothärmel, Lila Mekaoui, François Kazour et al. 1 citation

In a retrospective study of 22 adults with treatment-resistant depression and comorbid post-traumatic stress disorder who received esketamine nasal spray, trauma re-experiencing episodes occurred during treatment sessions. For 16 patients (72.7%) these episodes disappeared as sessions progressed. Treatment was stopped for 6 patients (27.3%) due to re-experiencing. Among those who continued esketamine, depression response rate was 45.5% and remission 22.7%; PTSD improvement rate was 45.5% and remission 18.2%. The findings suggest esketamine can be safely administered in this comorbid population and that trauma re-experiencing does not prevent clinical improvement.